Wikipedia:WikiProject Chemicals/Chembox validation/VerifiedDataSandbox and BD-1047: Difference between pages
(Difference between pages)
Content deleted Content added
Saving copy of the {{drugbox}} taken from revid 461508912 of page BD-1047 for the Chem/Drugbox validation project (updated: 'ChEMBL', 'CAS_number'). |
m link neurotoxicity |
||
| Line 1: | Line 1: | ||
{{Short description|Chemical compound}} |
|||
{{ambox | text = This page contains a copy of the infobox ({{tl|drugbox}}) taken from revid [{{fullurl:BD-1047|oldid=461508912}} 461508912] of page [[BD-1047]] with values updated to verified values.}} |
|||
{{Drugbox |
{{Drugbox |
||
| Verifiedfields = changed |
|||
| verifiedrevid = |
| verifiedrevid = 461748395 |
||
| IUPAC_name = N'-[2-(3,4-dichlorophenyl)ethyl]-N,N,N'-trimethylethane-1,2-diamine |
| IUPAC_name = N'-[2-(3,4-dichlorophenyl)ethyl]-N,N,N'-trimethylethane-1,2-diamine |
||
| image = BD- |
| image = BD-1047 Structure.svg |
||
| width = 200 |
| width = 200 |
||
<!--Clinical data--> |
<!--Clinical data--> |
||
| tradename = |
| tradename = |
||
| pregnancy_AU = |
| pregnancy_AU = |
||
| pregnancy_US = |
| pregnancy_US = |
||
| pregnancy_category = |
| pregnancy_category = |
||
| Line 16: | Line 17: | ||
| legal_US = |
| legal_US = |
||
| legal_status = |
| legal_status = |
||
| routes_of_administration = |
| routes_of_administration = |
||
<!--Pharmacokinetic data--> |
<!--Pharmacokinetic data--> |
||
| Line 23: | Line 24: | ||
| metabolism = |
| metabolism = |
||
| elimination_half-life = |
| elimination_half-life = |
||
| excretion = |
| excretion = |
||
<!--Identifiers--> |
<!--Identifiers--> |
||
| IUPHAR_ligand = 6680 |
|||
| CAS_number_Ref = {{cascite| |
| CAS_number_Ref = {{cascite|changed|??}} |
||
| CAS_number = |
| CAS_number = 138356-20-4 |
||
| UNII_Ref = {{fdacite|correct|FDA}} |
|||
| UNII = 1S3X75QGDO |
|||
| ATC_prefix = none |
| ATC_prefix = none |
||
| ATC_suffix = |
| ATC_suffix = |
||
| ChEMBL_Ref = {{ebicite|correct|EBI}} |
|||
| ChEMBL = 143360 |
| ChEMBL = 143360 |
||
| PubChem = 188914 |
| PubChem = 188914 |
||
| ChemSpiderID_Ref = {{chemspidercite|correct|chemspider}} |
| ChemSpiderID_Ref = {{chemspidercite|correct|chemspider}} |
||
| ChemSpiderID = 164154 |
| ChemSpiderID = 164154 |
||
| InChI = 1/C13H20Cl2N2/c1-16(2)8-9-17(3)7-6-11-4-5-12(14)13(15)10-11/h4-5,10H,6-9H2,1-3H3 |
|||
| InChIKey = MGVRNMUKTZOQOW-UHFFFAOYAY |
|||
| StdInChI_Ref = {{stdinchicite|correct|chemspider}} |
| StdInChI_Ref = {{stdinchicite|correct|chemspider}} |
||
| StdInChI = 1S/C13H20Cl2N2/c1-16(2)8-9-17(3)7-6-11-4-5-12(14)13(15)10-11/h4-5,10H,6-9H2,1-3H3 |
| StdInChI = 1S/C13H20Cl2N2/c1-16(2)8-9-17(3)7-6-11-4-5-12(14)13(15)10-11/h4-5,10H,6-9H2,1-3H3 |
||
| Line 43: | Line 46: | ||
<!--Chemical data--> |
<!--Chemical data--> |
||
| C=13 | H=20 | Cl=2 | N=2 |
| C=13 | H=20 | Cl=2 | N=2 |
||
| molecular_weight = 275.217 g/mol |
|||
| smiles = Clc1ccc(CCN(C)CCN(C)C)cc1Cl |
| smiles = Clc1ccc(CCN(C)CCN(C)C)cc1Cl |
||
| melting_point = |
| melting_point = |
||
| melting_high = |
| melting_high = |
||
}} |
}} |
||
'''BD-1047''' is a [[sigma receptor]] [[Antagonist (pharmacology)|antagonist]], selective for the [[Sigma-1 receptor|σ<sub>1</sub>]] subtype. It has effects in animal studies suggestive of [[antipsychotic]] activity and may also be useful in the treatment of [[neuropathic pain]].<ref name="pmid17085854">{{cite journal |vauthors=Skuza G, Rogóz Z |title=Effect of BD 1047, a sigma1 receptor antagonist, in the animal models predictive of antipsychotic activity |journal=Pharmacological Reports |volume=58 |issue=5 |pages=626–35 |year=2006 |pmid=17085854 }}</ref><ref name="pmid18946301">{{cite journal |vauthors=Roh DH, Kim HW, Yoon SY, Seo HS, Kwon YB, Kim KW, Han HJ, Beitz AJ, Na HS, Lee JH |title=Intrathecal injection of the sigma(1) receptor antagonist BD1047 blocks both mechanical allodynia and increases in spinal NR1 expression during the induction phase of rodent neuropathic pain |journal=Anesthesiology |volume=109 |issue=5 |pages=879–89 |date=November 2008|pmid=18946301 |doi=10.1097/ALN.0b013e3181895a83 |doi-access=free }}</ref> |
|||
More recent studies also suggest a novel role for BD-1047 in attenuating [[ethanol]]-induced [[neurotoxicity]] ''in vitro'', and additional research is being conducted on this compound as a possible pharmacotherapy for alcohol use disorder (AUD) <ref name="pmid27177604">{{cite journal |vauthors=Reynolds AR, Saunders MA, Prendergast MA |title=Ethanol Stimulates Endoplasmic Reticulum Inositol Triphosphate and Sigma Receptors to Promote Withdrawal-Associated Loss of Neuron-Specific Nuclear Protein/Fox-3. |journal=Alcohol Clin Exp Res |volume=40 |issue=7 |pages=1454–61 |year=2016 |pmid=27177604 |doi= 10.1111/acer.13097|pmc=6662182 }}</ref> |
|||
==References== |
|||
<references/> |
|||
{{Sigma receptor modulators}} |
|||
[[Category:Sigma antagonists]] |
|||
{{nervous-system-drug-stub}} |
|||